NR5A2 and pancreatic neoplasm: Collective data obtained from numerous in vitro and in vivo studies suggest that LRH-1 is a potential therapeutic target for several diseases including pancreatic cancer, breast cancer, colon cancer, inflammatory bowel disease and fatty liver disease.